Sirona Biochem Corp. faces financial challenges as a convertible debenture financing attempt fails due to lack of investor interest. Despite efforts to secure strategic investment, an agreement with Promura GmbH falls through, leading to the decision to liquidate its subsidiary, TFChem, in France. Allergan Aesthetics also backs out of a license agreement, adding to financial pressures. Sirona is evaluating options for its proprietary technologies, focusing on stabilizing carbohydrate molecules for cosmetic and drug discovery purposes. The company’s future remains uncertain as management navigates ongoing difficulties. For more information, visit www.sironabiochem.com.

Read more at GlobeNewswire: Sirona Biochem Update to Shareholders on Financial Status